Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱(chēng) 貨號(hào) 規(guī)格
Recombinant Shewanella putrefaciens 50S ribosomal protein L6 (rplF) CSB-YP397826STQ
CSB-EP397826STQ
CSB-BP397826STQ
CSB-MP397826STQ
CSB-EP397826STQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Shewanella putrefaciens 50S ribosomal protein L29 (rpmC) CSB-YP397827STQ
CSB-EP397827STQ
CSB-BP397827STQ
CSB-MP397827STQ
CSB-EP397827STQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Shewanella putrefaciens 50S ribosomal protein L3 (rplC) CSB-YP397828STQ
CSB-EP397828STQ
CSB-BP397828STQ
CSB-MP397828STQ
CSB-EP397828STQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Shewanella putrefaciens Ribonuclease P protein component (rnpA) CSB-YP397829STQ
CSB-EP397829STQ
CSB-BP397829STQ
CSB-MP397829STQ
CSB-EP397829STQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Metallosphaera sedula 50S ribosomal protein L2P (rpl2p) CSB-YP397830MNM
CSB-EP397830MNM
CSB-BP397830MNM
CSB-MP397830MNM
CSB-EP397830MNM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Metallosphaera sedula 50S ribosomal protein L18P (rpl18p) CSB-YP397831MNM
CSB-EP397831MNM
CSB-BP397831MNM
CSB-MP397831MNM
CSB-EP397831MNM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Metallosphaera sedula Leucine--tRNA ligase 1 (leuS1), partial CSB-YP397832MNM
CSB-EP397832MNM
CSB-BP397832MNM
CSB-MP397832MNM
CSB-EP397832MNM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Metallosphaera sedula Translation initiation factor 1A (eIF1A) CSB-YP397833MNM
CSB-EP397833MNM
CSB-BP397833MNM
CSB-MP397833MNM
CSB-EP397833MNM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Metallosphaera sedula 3-isopropylmalate dehydratase small subunit (leuD) CSB-YP397834MNM
CSB-EP397834MNM
CSB-BP397834MNM
CSB-MP397834MNM
CSB-EP397834MNM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Metallosphaera sedula Threonine--tRNA ligase (thrS), partial CSB-YP397835MNM
CSB-EP397835MNM
CSB-BP397835MNM
CSB-MP397835MNM
CSB-EP397835MNM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Metallosphaera sedula Probable N-glycosylase/DNA lyase (ogg) CSB-YP397836MNM
CSB-EP397836MNM
CSB-BP397836MNM
CSB-MP397836MNM
CSB-EP397836MNM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Metallosphaera sedula Type 2 DNA topoisomerase 6 subunit B (top6B), partial CSB-YP397837MNM
CSB-EP397837MNM
CSB-BP397837MNM
CSB-MP397837MNM
CSB-EP397837MNM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Metallosphaera sedula UPF0201 protein Msed_1787 (Msed_1787) CSB-YP397838MNM
CSB-EP397838MNM
CSB-BP397838MNM
CSB-MP397838MNM
CSB-EP397838MNM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Metallosphaera sedula V-type ATP synthase subunit E (atpE) CSB-YP397839MNM
CSB-EP397839MNM
CSB-BP397839MNM
CSB-MP397839MNM
CSB-EP397839MNM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Metallosphaera sedula V-type ATP synthase beta chain (atpB) CSB-YP397840MNM
CSB-EP397840MNM
CSB-BP397840MNM
CSB-MP397840MNM
CSB-EP397840MNM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Metallosphaera sedula Phosphoribosylformylglycinamidine synthase 2 (purL), partial CSB-YP397841MNM
CSB-EP397841MNM
CSB-BP397841MNM
CSB-MP397841MNM
CSB-EP397841MNM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Metallosphaera sedula Phenylalanine--tRNA ligase beta subunit (pheT), partial CSB-YP397842MNM
CSB-EP397842MNM
CSB-BP397842MNM
CSB-MP397842MNM
CSB-EP397842MNM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Metallosphaera sedula Isopentenyl-diphosphate delta-isomerase (fni) CSB-YP397843MNM
CSB-EP397843MNM
CSB-BP397843MNM
CSB-MP397843MNM
CSB-EP397843MNM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Metallosphaera sedula Probable tRNA threonylcarbamoyladenosine biosynthesis protein KAE1 homolog (Msed_2224) CSB-YP397844MNM
CSB-EP397844MNM
CSB-BP397844MNM
CSB-MP397844MNM
CSB-EP397844MNM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Metallosphaera sedula 30S ribosomal protein S17e (rps17e) CSB-YP397845MNM
CSB-EP397845MNM
CSB-BP397845MNM
CSB-MP397845MNM
CSB-EP397845MNM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過(guò)多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開(kāi)發(fā)過(guò)程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來(lái)自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開(kāi)發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來(lái)產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過(guò)多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過(guò)程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來(lái)選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見(jiàn)問(wèn)題。您可以單擊以下鏈接查看。http://m.cstxtech.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問(wèn),涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>